Gout Treatment and Clinical Considerations : The Role of Pegloticase, Colchicine, and Febuxostat
Copyright © 2023, Quintana et al..
Gout treatment has evolved rapidly in recent decades, and various drugs have been designed for acute and chronic management. Three medications used to treat gout include pegloticase, colchicine, and febuxostat. When prescribing these drugs, important factors to consider include pharmacokinetics, pharmacodynamics, population specifics, benefits, and contraindications. Pharmacokinetic considerations of each drug include absorption, distribution, metabolism, and elimination factors. Pharmacodynamics factors are assessed by their potential for toxicity and effects on serum uric acid levels. Additionally, the drug's targeted population must be considered to avoid unwanted complications in certain pre-existing conditions such as cardiovascular disease or glucose-6-dehydrogenase (G6PD) deficiency. In this paper, we aim to provide insight into the gout medications, pegloticase, colchicine, and febuxostat. This review will include their pharmacokinetics, pharmacodynamics, population specifics, benefits, and contraindications.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
|---|---|
| Enthalten in: |
Cureus - 15(2023), 10 vom: 07. Okt., Seite e46649 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Quintana, Michael J [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Colcrys (colchicine) |
|---|
| Anmerkungen: |
Date Revised 09.11.2023 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.7759/cureus.46649 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM364287780 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM364287780 | ||
| 003 | DE-627 | ||
| 005 | 20231226095125.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.7759/cureus.46649 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1214.xml |
| 035 | |a (DE-627)NLM364287780 | ||
| 035 | |a (NLM)37937020 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Quintana, Michael J |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Gout Treatment and Clinical Considerations |b The Role of Pegloticase, Colchicine, and Febuxostat |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 09.11.2023 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Copyright © 2023, Quintana et al. | ||
| 520 | |a Gout treatment has evolved rapidly in recent decades, and various drugs have been designed for acute and chronic management. Three medications used to treat gout include pegloticase, colchicine, and febuxostat. When prescribing these drugs, important factors to consider include pharmacokinetics, pharmacodynamics, population specifics, benefits, and contraindications. Pharmacokinetic considerations of each drug include absorption, distribution, metabolism, and elimination factors. Pharmacodynamics factors are assessed by their potential for toxicity and effects on serum uric acid levels. Additionally, the drug's targeted population must be considered to avoid unwanted complications in certain pre-existing conditions such as cardiovascular disease or glucose-6-dehydrogenase (G6PD) deficiency. In this paper, we aim to provide insight into the gout medications, pegloticase, colchicine, and febuxostat. This review will include their pharmacokinetics, pharmacodynamics, population specifics, benefits, and contraindications | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a colcrys (colchicine) | |
| 650 | 4 | |a gout | |
| 650 | 4 | |a krystexxa (pegloticase) | |
| 650 | 4 | |a uloric (febuxostat) | |
| 650 | 4 | |a uric acid | |
| 700 | 1 | |a Shum, Alika Z |e verfasserin |4 aut | |
| 700 | 1 | |a Folse, Michael S |e verfasserin |4 aut | |
| 700 | 1 | |a Ramesh, Prerana C |e verfasserin |4 aut | |
| 700 | 1 | |a Ahmadzadeh, Shahab |e verfasserin |4 aut | |
| 700 | 1 | |a Varrassi, Giustino |e verfasserin |4 aut | |
| 700 | 1 | |a Shekoohi, Sahar |e verfasserin |4 aut | |
| 700 | 1 | |a Kaye, Alan D |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cureus |d 2013 |g 15(2023), 10 vom: 07. Okt., Seite e46649 |w (DE-627)NLM24118083X |x 2168-8184 |7 nnns |
| 773 | 1 | 8 | |g volume:15 |g year:2023 |g number:10 |g day:07 |g month:10 |g pages:e46649 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.7759/cureus.46649 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 15 |j 2023 |e 10 |b 07 |c 10 |h e46649 | ||